Drugs / Autologous nano CD5-CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07678307 | Jun 2026 → Dec 2027 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous nano CD5-CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07678307 ↗ |
| Action | Deplete | “These are your own immune cells that have been changed in a lab to recognize and kill cancer cells.” NCT07678307 ↗ |
| Modality | Cell therapy | “Autologous CD5-targeted CAR-T cells engineered with a novel nano antibody-based chimeric antigen receptor.” NCT07678307 ↗ |
| Route | Intravenous | “single intravenous infusion of autologous nano CD5-CAR T cells” NCT07678307 ↗ |